Exelixis, INC 10-Q quarterly reports

Exelixis, an oncology company, reported significant revenue and net income growth in Q3 2025, driven by strong CABOMETYX sales and positive clinical trial results for zanzalintinib.

Exelixis announced robust product revenue growth, positive Phase 3 results for zanzalintinib in colorectal cancer, and new regulatory approvals for CABOMETYX, alongside ongoing share repurchases.

Exelixis announces a significant increase in net product revenues and total revenues for the first quarter of 2025, primarily driven by the continued success of CABOMETYX.

Exelixis' Q3 2024 financial results show a significant increase in revenue and net income, primarily driven by strong sales of its flagship product, Cabometyx.

Exelixis' Q2 2024 financial results show significant revenue growth driven by Cabometyx sales and strategic collaborations, alongside pipeline advancements.

Exelixis reported a 4% increase in total revenue for the first quarter of 2024, alongside a restructuring plan aimed at cost reduction.